ReviewPatient related outcome measures2022
Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE
Review in Patient related outcome measures, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.Breast cancer research and treatment · 2025Pooled it
- Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies.Current drug safety · 2024Pooled it
- Prevalence of patient-reported and clinician-graded cognitive symptomatic adverse events in older patients with advanced cancer.JNCI cancer spectrum · 2026Trial
- Trial
- Trial
- Efficacy and safety of Ashwagandha (Journal of medicine and life · 2025Trial
- Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).JNCI cancer spectrum · 2025Trial
- Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.Journal of the National Cancer Institute · 2024Trial
- Adverse events in gynaecological radiotherapy: Better Reporting, Interpretation and Dissemination to Generate Evidence (BRIDGE).Technical innovations & patient support in radiation oncology · 2026Article
- Measuring toxicity better: patient-reported outcome-informed calibration for CTCAE assessment.Translational cancer research · 2026Article
- Review
- Article
- Patients' perspective in anal cancer.ESMO gastrointestinal oncology · 2026Review
- Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials.Cancers · 2026Article
- A single item for overall side effect impact: Association with clinician-reported adverse events and global health.Clinical trials (London, England) · 2026Article
- Article
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Quality of Life Trajectories With Integration Into Electronic Health Records for High-Resolution Patient Outcomes: Algorithm Development and Validation Study.Journal of medical Internet research · 2026Article
- Pretreatment naive T cells are associated with severe irAE following PD-1/CTLA-4 checkpoint blockade for melanoma.JCI insight · 2026Article
- Effectiveness of Compression Therapy for the Prevention of Taxane-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inclusion of the patient perspective in the reporting of symptomatic adverse events provides different and complementary information to clinician reporting using the Common Terminology Criteria for Adverse Events (CTCAE). The National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.